US 12,414,969 B2
Methods and compositions for reducing clostridium difficile infection
Eric Pamer, Guilford, CT (US); Charlie Buffie, New York, NY (US); and Peter McKenney, New York, NY (US)
Assigned to Memorial Sloan-Kettering Cancer Center, New York, NY (US)
Filed by MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed on Oct. 17, 2022, as Appl. No. 18/047,167.
Application 18/047,167 is a division of application No. 16/523,414, filed on Jul. 26, 2019, granted, now 11,471,495.
Application 16/523,414 is a continuation of application No. 15/312,610, abandoned, previously published as PCT/US2015/031627, filed on May 19, 2015.
Claims priority of provisional application 62/000,308, filed on May 19, 2014.
Prior Publication US 2023/0190825 A1, Jun. 22, 2023
Int. Cl. A61K 35/74 (2015.01); A61K 38/44 (2006.01); A61K 45/06 (2006.01); C12N 9/00 (2006.01); C12N 9/04 (2006.01); C12Q 1/26 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 38/443 (2013.01); A61K 45/06 (2013.01); C12N 9/0006 (2013.01); C12Q 1/26 (2013.01); C12Y 101/01159 (2013.01)] 18 Claims
 
1. A composition comprising two or more purified or isolated bacteria or spores thereof, the composition comprising:
a first purified or isolated bacteria or spores thereof comprising Clostridium scindens;
a second isolated or purified bacteria or spores thereof comprising Blautia hansenii or Barnesiella intestihominis; and
a secondary bile acid selected from the group consisting of a deoxycholic acid, a lithocholic acid, and a combination thereof,
wherein the two or more purified or isolated bacteria or spores thereof are in a formulation for administration to a subject, wherein at least one of the two or more purified or isolated bacteria or spores thereof is capable of converting a primary bile acid to a secondary bile acid, and
wherein the composition comprises a capsule.